Olmutinib - CAS 1353550-13-6
Catalog number:
B0084-470842
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C26H26N6O2S
Molecular Weight:
486.18
COA:
Inquire
Targets:
BTK | EGFR
Description:
Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-470842 200 mg $199 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Related CAS:
1842366-97-5 (HCl); 1802181-20-9 (deleted CAS#)
Appearance:
Light yellow solid powder
Synonyms:
N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; HM61713; HM 61713; HM-61713; BI 1482694; BI-1482694; BI1482694; Olmutinib
Solubility:
DMSO 97 mg/mL (199.34 mM)
MSDS:
Inquire
InChIKey:
FDMQDKQUTRLUBU-UHFFFAOYSA-N
InChI:
1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
Canonical SMILES:
C=CC(NC1=CC=CC(OC2=C3C(C=CS3)=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1)=O
Current Developer:
Boehringer Ingelheim; Hanmi Pharmaceutical; ZAI Lab
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related BTK Products


CAS 1202759-32-7 CNX-774

CNX-774
(CAS: 1202759-32-7)

CNX-774 is a potent Btk inhibitor (IC50 < 1 nM)

CAS 366017-09-6 Mubritinib

Mubritinib
(CAS: 366017-09-6)

Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...

ONO-4059
(CAS: 1351636-18-4)

ONO-4059, a BTK inhibitor, has been found to have potential effect against sorts of malignancies by influencing the B-cell development. It is currently under Ph...

CAS 1415823-73-2 Evobrutinib

Evobrutinib
(CAS: 1415823-73-2)

Evobrutinib is a highly selective inhibitor of Bruton's tyrosin kinase (Btk) inhibitor.

CAS 1202757-89-8 AVL-292

AVL-292
(CAS: 1202757-89-8)

AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplas...

CAS 451493-31-5 AV-412 Tosylate

AV-412 Tosylate
(CAS: 451493-31-5)

AV-412 is a dual EGFR/ErbB2 kinase inhibitor. It completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 ...

CAS 330786-25-9 PCI 29732

PCI 29732
(CAS: 330786-25-9)

Potent BTK inhibitor (IC50 = 0.3 nM). Blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells.

CAS 910232-84-7 CGI1746

CGI1746
(CAS: 910232-84-7)

CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 has exqui...

TPC-064

TPC-064 is a novel mutant-selective inhibitor of EGFR, which plays a role in NSCLC and therefore becomes a key target for cancer therapy. TPC-064 can selectivel...

EAI045
(CAS: 1942114-09-1)

EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mut...

CAS 388082-77-7 Lapatinib Ditosylate

Lapatinib Ditosylate
(CAS: 388082-77-7)

Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth ...

CAS 196612-93-8 Falnidamol

Falnidamol
(CAS: 196612-93-8)

Falnidamol, also known as BIBX 1382, is a pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epider...

NT113
(CAS: 1398833-56-1)

NT113 is a pan-ERBB inhibitor with high brain penetrance. It can inhibit the growth of glioblastoma xenografts with EGFR amplification. NT113 is active against ...

CAS 1360053-81-1 AVL-292 benzenesulfonate

AVL-292 benzenesulfonate
(CAS: 1360053-81-1)

AVL-292 benzenesulfonate is a covalent, highly selective, orally active small molecule inhibitor of Btk with IC50 value of 0.5 nM; &gt;1400-fold selectivity ove...

MTX-211
(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

ONO-4059 analogue
(CAS: 1351635-67-0)

ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.

CAS 1133432-46-8 GDC-0834

GDC-0834
(CAS: 1133432-46-8)

GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabol...

RN983
(CAS: 1423129-83-2)

RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an ...

CAS 1412418-47-3 Btk inhibitor 1

Btk inhibitor 1
(CAS: 1412418-47-3)

Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.

CAS 1421373-66-1 AZD-9291 mesylate

AZD-9291 mesylate
(CAS: 1421373-66-1)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

Chemical Structure

CAS 1353550-13-6 Olmutinib

Quick Inquiry

Verification code

Featured Items